Rohit Singh, MD
@RohitBanwar
Followers
550
Following
5K
Media
15
Statuses
286
Medical Oncologist, Asst Professor @UVMMedCenter; alum editorial fellow@JCO_ASCO; member @ASCOTECAG. Immuno-Oncology, thoracic Oncology, Melanoma
Vermont, USA
Joined August 2011
Our #ASCO25 JCO Central lounge in Room S403b is open to all today from noon to 5 pm. Info & programming: https://t.co/bCFjyiXM0v Today @ 11:45am #JCO EIC @DrJFriedberg & Dr. Kathy Miller will host a grant writing & publishing workshop in the Trainee & Early Career Lounge.
0
5
11
📚 Join us at #ASCO25 for Publication 101: Peer Review & Becoming a Successful Author 🗓️ June 2 | ⏰ 10:15–11:15 AM 📍Trainee & Early Career Lounge Get practical tips to boost your academic writing, peer-review & publishing success! #OncTwitter #ASCO #ASCOTECAG #UVM
0
1
6
Will you be at #ASCO25? Don’t miss the Trainee & Early Career Lounge (TEC) — the ultimate space to recharge 🛋️, sip on ☕, and connect with fellow students, residents, fellows, and junior faculty! 🌟 Highlights: 📋 Protocol to Publication Roundtable 📱 Leveraging Social Media
2
31
62
🚨Mark your calendars for the @ASCOTECAG town hall on ways to navigate #ASCO25! From logistics, to intentional planning and to enjoyment! 💫"So You’re Going to the ASCO Annual Meeting… What to Do to Make the Most of It" 📅 Thu 5/22 3-4 pm ET 👉Register https://t.co/EWIMDQzENG
0
46
102
Navigating the J1visa waiver while building a career in HemeOnc? We wrote about the challenges, strategies, and tips for finding a heme/onc job in the U.S. on a J-1 visa — while staying true to your long-term goals. @IvyLorena_Md @ASCO @uvmvermont
#MedTwitter #Oncology #IMG
We encourage you to check out our article on tips for finding a HemeOnc job in the U.S. while on a J1 visa. It offers practical advice from individuals who have navigated the same process! @ASCO #ASCOConnections @RohitBanwar
0
7
25
🚨 Don’t miss out on the ASCO Editorial Fellowship! 🌟 As a proud alumnus, I strongly recommend it. @JCO_ASCO @ASCO @ASCOTECAG 📚 Learn from the experts ✍️ Valuable insights the editorial process 🌍 Expand your professional network 🔗
ascopubs.org
0
0
10
Up to 40% of cancers are preventable with lifestyle changes: avoid tobacco, eat healthy, stay active, and regular cancer screenings. Take control of your health today. #CancerAwareness #CancerPrevention #HealthTips #EarlyDetection #Wellness
https://t.co/2b9VHFxx1i
pubmed.ncbi.nlm.nih.gov
In 2018, the authors reported estimates of the number and proportion of cancers attributable to potentially modifiable risk factors in 2014 in the United States. These data are useful for advocating...
1
1
6
“Officially board-certified in Hematology and Oncology! Grateful for the journey, the support, and the opportunity to make a difference in the lives of patients. Excited for what’s ahead! #BoardCertified #Oncology” @ASCOTECAG @ASCO @ASH_hematology #HEMEONC
10
2
112
Planning your career after fellowship? Our article on @ASCO connection explores the pros & cons of academia, community & hybrid practices! A practical guide to help fellows make informed decisions! @MatthewKurianMD @rajatthawani @ASCOTECAG @OhioStateMedOnc @HemOncFellows
3
20
66
Jumpstart your job search with our @ASCO Connection article! Uncover secrets for navigating your career post-fellowship. We discuss the pros/cons of community, academic, and hybrid practices to help you find your ideal path. @royaryam @MatthewKurianMD
https://t.co/q3o7fnHJ3n
connection.asco.org
0
5
8
International Faculty: Upal Basu Roy from @LUNGevity, @RamalingamMD from @WinshipAtEmory and @GsrivastavaMD from the @US_FDA
1
3
10
FDA approves #Durvalumab for limited-stage #SCLC after the ADRIATIC trial shows a game-changing median OS of 55.9 months vs 33.4 months! A new standard of care. #LungCancer #Oncology #lcsm
fda.gov
On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for limited-stage small cell lung cancer (LS-SCLC).
1
2
14
If you’re available at 11 am ET tomorrow, we’d love to have you join the discussion: https://t.co/vXMjsIDST9
#lcam #lcsm #cme #ce
0
3
8
Exciting times in #NSCLC with multiple immunotherapy approvals! 🎉 But navigating these options can be complex. Glad to partner with @OncLearnNetwork to create patient case-based education, bridging the gap between advancements and real-world application. Let’s ensure these
0
2
20
From fee-for-service to value-based care—in the final hr of #ASCOQLTY24, we discussed how the future of care delivery hinges on aligning reimbursement with patient needs/outcomes. This can be driven by strategic policy & legislative efforts, possible even in a gridlocked Congress
Dr @QasimHussainiMD #ASCOQLTY24 “How Are We Going to Pay for This?” The Future of Reimbursement Sustainability
0
5
36
#Osimertinib, FDA-approved for stage-III EGFR-mNSCLC after chemoXRT, #LAURA Ph-III trial. Remarkable PFS of 39.1 months compared to 5.6 months with a HR of 0.16. The 2-year PFS; 65% vs 13%, along with enhanced CNS PFS. Grade ≥3 AE 35% vs 12%. #LungCancer #CancerResearch
0
2
14
New data: Most doctors take less than 3 weeks of vacation a year, and 70% work while on vacation. Both factors were associated with higher rates of burnout. We have to stop the vacation shaming and find realistic strategies for coverage without burdening our colleagues.
39
254
2K
BREAKING: @US_FDA Approves Pembrolizumab Plus Chemo for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma #lcsm #oncology
https://t.co/aAuceH97Pq
0
2
6
FDA approves subcutaneous form of atezolizumab for use where IV already approved (including NSCLC and SCLC). Based on IMscin001 showing OS, RR, PROs, safety were similar with far shorter administration time. https://t.co/UTWMPi9M4a
targetedonc.com
The subcutaneous version of the cancer treatment atezolizumab is approved in all adult intravenous indications, including in lung, liver, and skin cancers.
2
32
111